Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

According to Reuters, the grocery retailer notified Express Scripts in September 2022 of its plan to terminate the pharmacy ...

True, AbbVie's most important drug through most of those years, rheumatoid arthritis medicine Humira, is now out of patent exclusivity. However, the company is handling that loss just fine.

These strong results demonstrate AbbVie's resilience in navigating the transition away from its former flagship product, as Humira sales decreased by 49% to $1.68 billion in the fourth quarter.

AbbVie (NYSE: ABBV) is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira’s patent cliff are ...

The demand for those two treatments offset continuing falling sales of its former blockbuster medicine, Humira. AbbVie raised its long-term outlook for Skyrizi and Rinvoq revenue. AbbVie (ABBV ...

AbbVie Inc.’s stock rose 7.7% Friday to lead ... delivered growth needed to offset declining sales of its blockbuster Humira. The stock is on track for its biggest one-day percentage increase ...

“We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity,” said Robert A.

As for the topline, despite the generic threat faced by the company's former bestseller Humira, AbbVie (NYSE:ABBV) exceeded Street forecasts, recording $15.1B in revenue with ~6% YoY growth as the ...

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset.

AbbVie has been looking for drugs to replace Humira, which was long its biggest revenue contributor, but since losing patent protection has been under pressure from biosimilars. Sales plunged 49% ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...